Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 6901 AL 6915

The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders II: Alzheimer's disease

da Rocha MD, Viegas FP, Campos HC, Nicastro PC, Fossaluzza PC, Fraga CA, Barreiro EJ, Viegas C Jr.

CNS Neurol Disord Drug Targets. 2011 Mar;10(2):251-70. doi: 10.2174/187152711794480429.

Mitophagy in neurodegeneration: an opportunity for therapy?

Santos RX, Correia SC, Carvalho C, Cardoso S, Santos MS, Moreira PI.

Curr Drug Targets. 2011 Jun;12(6):790-9. doi: 10.2174/138945011795528813.

Developing predictive CSF biomarkers-a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine

Flood DG, Marek GJ, Williams M.

Biochem Pharmacol. 2011 Jun 15;81(12):1422-34. doi: 10.1016/j.bcp.2011.01.021. Epub 2011 Feb 3.

Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim

Weinreb O, Mandel S, Bar-Am O, Amit T.

J Neural Transm (Vienna). 2011 Mar;118(3):479-92. doi: 10.1007/s00702-011-0597-6. Epub 2011 Mar 1.

Metal ions, Alzheimer's disease and chelation therapy

Budimir A.

Acta Pharm. 2011 Mar;61(1):1-14. doi: 10.2478/v10007-011-0006-6.

Correlates of care relationship mutuality among carers of people with Alzheimer's and Parkinson's disease

Shim B, Landerman LR, Davis LL.

J Adv Nurs. 2011 Aug;67(8):1729-38. doi: 10.1111/j.1365-2648.2011.05618.x. Epub 2011 Apr 4.

Deep brain stimulation emerging indications

Tierney TS, Sankar T, Lozano AM.

Prog Brain Res. 2011;194:83-95. doi: 10.1016/B978-0-444-53815-4.00015-7.

Neuroprotection in metabolism-based therapy

Hartman AL.

Epilepsy Res. 2012 Jul;100(3):286-94. doi: 10.1016/j.eplepsyres.2011.04.016. Epub 2011 Aug 26.

Therapeutic intervention at cellular quality control systems in Alzheimer's and Parkinson's diseases

Arduino DM, Esteves AR, Silva DF, Martins-Branco D, Santos D, Pimentel DF, Cardoso SM.

Curr Pharm Des. 2011;17(31):3446-59. doi: 10.2174/138161211798072481.

Targeting HDACs: a promising therapy for Alzheimer's disease

Xu K, Dai XL, Huang HC, Jiang ZF.

Oxid Med Cell Longev. 2011;2011:143269. doi: 10.1155/2011/143269. Epub 2011 Sep 20.

Multimodal drugs and their future for Alzheimer's and Parkinson's disease

Van der Schyf CJ, Geldenhuys WJ.

Int Rev Neurobiol. 2011;100:107-25. doi: 10.1016/B978-0-12-386467-3.00006-6.

Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32)

Olin JT, Bhatnagar V, Reyes P, Koumaras B, Meng X, Brannan S.

Int J Geriatr Psychiatry. 2010 Apr;25(4):419-26. doi: 10.1002/gps.2355.

Targeting Abeta and tau in Alzheimer's disease, an early interim report

Golde TE, Petrucelli L, Lewis J.

Exp Neurol. 2010 Jun;223(2):252-66. doi: 10.1016/j.expneurol.2009.07.035. Epub 2009 Aug 27.

Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia

Darreh-Shori T, Jelic V.

Expert Opin Drug Saf. 2010 Jan;9(1):167-76. doi: 10.1517/14740330903439717.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias